As expected, 889-S1 tumours were sensitive to PD-1 blockade treatment; USP12 silencing, however, substantially desensitized tumours to anti-PD-1 therapy, as evidenced by tumour incidence and volume (Fig. 6a). Here, USP12 is linked to neoplasm.